S. 832

Status: In committee

EPIC Act of 2025

Sponsored by Thom Tillis (Republican-NC)

Topics

Cosponsors

Actions

Roll calls

Amendments

Related bills

Actions

Mar 4, 2025 · Library of Congress

Introduced in Senate

Mar 4, 2025 · Senate

Read twice and referred to the Committee on Finance.

Latest activity

July 2026

Lobbying reported · Sanofi US Services · Jul 21

Sanofi US Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Sanofi US Services — $920,000

BillsH.R. 1 H.R. 5376 H.R. 6423 H.R. 7174 H.R. 7834 H.R. 8698 H.R. 9102 S. 43 S. 832 S. 864 S. 1339 S. 1542 S. 3131 S. 4504

Lobbying reported · EMD Serono · Jul 21

EMD Serono reported 2nd Quarter (Apr 1 - June 30) lobbying for EMD Serono — $700,000

BillsH.R. 1 H.R. 220 H.R. 1492 H.R. 3838 H.R. 4317 H.R. 6703 H.R. 6797 H.R. 8800 S. 832 S. 864 S. 882 S. 891 S. 1071 S. 2296 S. 3345

Lobbying reported · Biotechnology Innovation Organization · Jul 21

Biotechnology Innovation Organization reported 2nd Quarter (Apr 1 - June 30) lobbying for Biotechnology Innovation Organization — $2,360,000

Lobbying reported · Biogen · Jul 20

Biogen reported 2nd Quarter (Apr 1 - June 30) lobbying for Biogen — $1,060,000

BillsH.R. 1262 H.R. 1492 H.R. 3747 H.R. 4317 H.R. 6130 H.R. 6837 S. 832 S. 864 S. 3267 S. 3345

Lobbying reported · Bayer · Jul 20

Bayer reported 2nd Quarter (Apr 1 - June 30) lobbying for Bayer — $1,820,000

BillsH.R. 1492 H.R. 1897 H.R. 3160 H.R. 3269 H.R. 7366 H.R. 7567 H.R. 9171 H.R. 9260 S. 832 S. 1546 S. 1553 S. 3122 S. 3677 S. 3788

Lobbying reported · Dla Piper LLP (US) · Jul 20

Dla Piper LLP (US) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $60,000

BillsS. 832

Lobbying reported · Dla Piper LLP (US) · Jul 20

Dla Piper LLP (US) reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $60,000

BillsH.R. 1492 H.R. 1672 S. 832

Lobbying reported · Forbes-Tate · Jul 20

Forbes-Tate reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $50,000

BillsH.R. 1672 H.R. 3037 S. 832 S. 1500

Lobbying reported · Johnson & Johnson Services · Jul 20

Johnson & Johnson Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Johnson & Johnson Services — $1,440,000

Lobbying reported · Pharmaceutical Research and Manufacturers of America (PhRMA) · Jul 20

Pharmaceutical Research and Manufacturers of America (PhRMA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $7,360,000

Lobbying reported · Soleno Therapeutics · Jul 20

Soleno Therapeutics reported 2nd Quarter (Apr 1 - June 30) lobbying for Soleno Therapeutics — $70,000

BillsH.R. 1414 H.R. 1492 H.R. 7118 S. 832

Lobbying reported · Williams And Jensen · Jul 20

Williams And Jensen reported 2nd Quarter (Apr 1 - June 30) lobbying for PhRMA — $50,000

BillsH.R. 1 H.R. 1492 S. 832

Lobbying reported · Monument Advocacy · Jul 20

Monument Advocacy reported 2nd Quarter (Apr 1 - June 30) lobbying for PhRMA — $90,000

BillsH.R. 1 H.R. 1492 H.R. 7194 S. 832

Lobbying reported · Boehringer Ingelheim USA Corporation, Formerly Reported As Boehringer Ingelheim Pharmaceuticals · Jul 20

Boehringer Ingelheim USA Corporation, Formerly Reported As Boehringer Ingelheim Pharmaceuticals reported 2nd Quarter (Apr 1 - June 30) lobbying for Boehringer Ingelheim USA — $710,000

BillsH.R. 842 H.R. 1492 H.R. 7567 S. 339 S. 832

Lobbying reported · The ALS Association · Jul 20

The ALS Association reported 2nd Quarter (Apr 1 - June 30) lobbying for The ALS Association — $30,000

Lobbying reported · Novartis · Jul 20

Novartis reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $1,410,000

Lobbying reported · Takeda Pharmaceuticals America · Jul 20

Takeda Pharmaceuticals America reported 2nd Quarter (Apr 1 - June 30) lobbying for Takeda Pharmaceuticals America — $610,000

BillsH.R. 1 S. 832

Lobbying reported · Neurocrine Biosciences · Jul 20

Neurocrine Biosciences reported 2nd Quarter (Apr 1 - June 30) lobbying for Neurocrine Biosciences — $940,000

BillsH.R. 1492 H.R. 7024 H.R. 7623 S. 832

Lobbying reported · Public Citizen · Jul 20

Public Citizen reported 2nd Quarter (Apr 1 - June 30) lobbying for Public Citizen — $99,577

Lobbying reported · The Mcmanus Group · Jul 20

The Mcmanus Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $60,000

BillsH.R. 1492 H.R. 4299 H.R. 9504 S. 832